Funding for this research was provided by:
Future Generation Global
Received: 25 August 2020
Accepted: 14 April 2021
First Online: 12 May 2021
: All trial sites included in this study have received ethics approval. Ethics approval has been granted via Sydney Local Health District’s Human Research Ethics Committee (HREC) (Protocol No X18–0499 & HREC/18/RPAH/715) for the following trial sites: <i>headspace</i> Ashfield, Bondi Junction, Hurstville, Miranda, Camperdown, and Edinburgh North.As stated above under ‘Participant recruitment’, interested participants will need to contact the Implementation Officer (via email or in person on-site) to receive a Participant Information Sheet, and the Implementation Officer will then answer any outstanding questions regarding participation. If they would like to participate in the study, the potential participant will be provided with a written Participant Consent Form (provided in-person, on-site; or via email) which includes options for them to consent to receiving links to the baseline and follow up online surveys and semi-structured interviews, as well as to consent to having their interview scribed and audio-recorded. For semi-structured interviews, informed consent will be confirmed by the research team prior to the beginning of the session on the day.
: Not applicable.
: IBH was an inaugural Commissioner on Australia’s National Mental Health Commission (2012–18). He is the Co-Director, Health and Policy at The University of Sydney’s Brain and Mind Centre (BMC). The BMC operates an early-intervention youth services at Camperdown under contract to <i>headspace</i>. IBH is the Chief Scientific Advisor to, and a 5% equity shareholder in, InnoWell Pty Ltd. InnoWell was formed by the University of Sydney (45% equity) and PwC (Australia; 45% equity) to deliver the $30 million Australian Government-funded Project Synergy (2017–20; a three-year program for the transformation of mental health services) and to lead transformation of mental health services internationally through the use of innovative technologies.Ms. Tracey Davenport is now the Director (Research and Evaluation), Design and Strategy Division, at the Australian Digital Health Agency. Other authors on this paper have no conflicts of interest to disclose.